Alnylam Pharmaceuticals Beats Non-GAAP EPS and Revenue Estimates

Trending News 🌥️

Alnylam Pharmaceuticals ($NASDAQ:ALNY) is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). The company recently reported its Non-GAAP EPS of -$1.06, which beat analysts’ expectations by $0.37.

Additionally, its revenue of $319.29M was significantly higher than the forecasted amount of $6.76M. This marks another successful financial quarter for the company. Alnylam Pharmaceuticals is continuing to focus on its research and development efforts in order to develop new treatments and therapeutic options for patients. The company has several drugs in various stages of development, and is pursuing a range of different therapeutic areas, including cardiovascular, infectious diseases, central nervous system disorders, metabolic disorders, and rare diseases. The company is also continuing to look for strategic partnerships and collaborations with third parties in order to further its research and development efforts. Alnylam Pharmaceuticals has established partnerships with some of the world’s leading biopharmaceutical companies and is focused on delivering innovative solutions to meet the needs of patients. Overall, Alnylam Pharmaceuticals continues to perform well financially, while also continuing to focus on delivering innovative treatments and advancing its research and development initiatives. The company’s strong financial performance and ongoing commitment to developing new treatments shows great promise for the future of Alnylam Pharmaceuticals.

Earnings

In the latest earning report of Fiscal Year 2022 Quarter 4 ending December 31 2022, ALNYLAM PHARMACEUTICALS managed to exceed expectations both in non-GAAP earnings per share (EPS) and total revenue. It reported a total revenue of 335.04M USD, showing an impressive 29.6% increase from its previous year’s total revenue of 163.56M USD. Despite this dip in net income, ALNYLAM PHARMACEUTICALS still managed to beat non-GAAP EPS and revenue estimates.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Alnylam Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Alnylam Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Alnylam Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Alnylam Pharmaceuticals are shown below. More…

Market Price

On Thursday, ALNYLAM PHARMACEUTICALS stock opened at $201.7 and closed at $205.4, representing a 3.0% increase from the previous closing price of $199.5. The revenue growth was primarily driven by higher sales from its blockbuster drug Onpattro, a treatment for hereditary transthyretin-mediated amyloidosis. With this impressive financial performance, investors are now optimistic that ALNYLAM PHARMACEUTICALS will continue to deliver solid results in the coming quarters. Live Quote…

Analysis

GoodWhale has conducted an analysis of ALNYLAM PHARMACEUTICALS‘s wellbeing and determined that it is a high risk investment in terms of financial and business aspects. To assess this, our team has detected five risk warnings in its income sheet, balance sheet, cashflow statement, non financial and financial journal. For more detailed information on these warnings, become a registered user of GoodWhale and check it out. We believe that understanding the risks associated with investing in ALNYLAM PHARMACEUTICALS is important to make the right decisions. That’s why we strive to provide accurate and detailed assessments of companies’ well-being so our users can make the most informed decisions. More…

Peers

The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s competitors include Regeneron Pharmaceuticals Inc, Intellia Therapeutics Inc, and Novartis AG.

– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)

As of 2022, Regeneron Pharmaceuticals Inc has a market cap of 79.02B and a Return on Equity of 19.7%. The company is a biotech company that focuses on the discovery, development, and commercialization of medicines for the treatment of serious medical conditions.

– Intellia Therapeutics Inc ($NASDAQ:NTLA)

Intellia Therapeutics is a gene-editing company that focuses on developing therapeutics to treat serious diseases. The company has a market cap of $3.96 billion as of 2022 and a return on equity of -26.91%. Intellia’s gene-editing technology is based on CRISPR-Cas9, which is a naturally occurring bacterial system that can be used to target and edit specific genes. The company’s pipelines include programs for sickle cell disease, beta thalassemia, Huntington’s disease, and transthyretin amyloidosis.

– Novartis AG ($LTS:0QM7)

Novartis AG is a global pharmaceutical company with a market cap of 169.13B as of 2022. It has a Return on Equity of 24.65%. The company focuses on the discovery, development, and commercialization of healthcare products. Novartis’s products include over-the-counter and prescription drugs, vaccines, and diagnostic tools. The company has operations in over 140 countries and its products are sold in 180 countries.

Summary

Alnylam Pharmaceuticals had a positive earnings report. Their Non-GAAP EPS of -$1.06 beat analysts’ expectations by $0.37 and their revenue of $319.29M beat estimates by $6.76M. This good news had a direct effect on their stock price, as it moved up on the same day. Investors may be encouraged by the strong numbers, making Alnylam a potentially attractive investment option. Alnylam has a strong pipeline of new developments, which could potentially lead to even bigger gains in the future.

However, investors should do their own research and always consider the risks associated with investing in any company.